|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,668,981
United States Patent 9,668,981, titled "SELECTIVE RETROVIRAL AND RETROTRANSPOSON POLYNUCLETIDE ANALOGS AND METHODS FOR THEIR USE," issued on June 6, 2017, to ViiV Healthcare B.V. The patent covers specific nucleotide analogs designed to inhibit retroviral and retrotransposon replication. These analogs are characterized by a specific chemical structure, including a furanose or modified furanose ring and a modified base. The claims are directed towards the compounds themselves, pharmaceutical compositions containing these compounds, and methods of treating viral infections, particularly those caused by human immunodeficiency virus (HIV).
What is the Core Technology Protected by Patent 9,668,981?
The patent protects novel nucleotide analogs that function as chain terminators during viral DNA synthesis. The core innovation lies in the specific structural modifications to the nucleoside or nucleotide backbone and/or the base, which confers selective activity against viral enzymes (reverse transcriptase) while minimizing interaction with human cellular DNA polymerases. This selectivity is crucial for reducing toxicity and improving therapeutic efficacy.
The patent's claims define these analogs through Markush structures and specific examples. Key structural features include modifications to the 2', 3', or 4' positions of the furanose ring and alterations to the purine or pyrimidine base. For instance, Claim 1 recites a compound of Formula I, which involves a specific heterocyclic base attached to a modified carbohydrate moiety. The modifications described aim to prevent the addition of subsequent nucleotides to a growing DNA chain once the analog is incorporated.
Which Viral and Non-Viral Targets Does the Patent Encompass?
The patent explicitly targets retroviruses, with a primary focus on Human Immunodeficiency Virus (HIV). The rationale for this focus stems from the mechanism of action: the analogs are designed to inhibit the reverse transcriptase enzyme, a critical component of the retroviral replication cycle. HIV utilizes reverse transcriptase to convert its RNA genome into DNA, which is then integrated into the host cell's genome. By blocking this step, the analogs prevent viral replication.
Beyond HIV, the patent also broadly claims coverage for retrotransposons. Retrotransposons are mobile genetic elements that replicate via an RNA intermediate and reverse transcriptase, similar to retroviruses. While their relevance in human disease is less direct than HIV, they are implicated in genetic instability and certain conditions. The inclusion of retrotransposons suggests a broader potential application in addressing genetic disorders or other conditions where retrotransposon activity is a factor, although the primary commercial and therapeutic focus appears to be antiviral.
The patent's claims are broad enough to potentially cover analogs that exhibit activity against other viruses that rely on a reverse transcriptase or a similar DNA polymerase for replication, provided the claimed structural features are present and the activity is demonstrated. However, the written description and examples are heavily weighted towards HIV.
What are the Key Claims of Patent 9,668,981?
Patent 9,668,981 has a set of 20 claims, with Claims 1-10 directed to compounds and pharmaceutical compositions, and Claims 11-20 directed to methods of use.
Key Compound Claims (Claims 1-10):
- Claim 1: This independent claim defines a compound of Formula I. The formula specifies a heterocyclic base, typically a purine or pyrimidine derivative, attached to a modified furanose ring. The modifications to the furanose ring are crucial, particularly at the 2' and/or 3' positions, often involving substituents that prevent further phosphodiester bond formation. The claim details various substituents (R1, R2, R3, R4, R5, R6, R7, X, Y, Z) that can be present on the base and the carbohydrate moiety, defining a broad genus of compounds.
- Claim 2: Dependent on Claim 1, this claim narrows the scope by specifying particular types of heterocyclic bases, such as adenine, guanine, cytosine, thymine, uracil, or their analogs.
- Claim 3: Dependent on Claim 1, this claim further defines the carbohydrate moiety, specifying that the furanose ring is a 2'-deoxyribofuranose or a 2',3'-dideoxyribofuranose or a 3'-deoxyribofuranose.
- Claims 4-7: These claims specify particular substituents and stereochemical configurations at various positions on the furanose ring, further refining the chemical space covered. For example, they might define specific moieties at the 3' position to act as chain terminators.
- Claim 8: This claim covers pharmaceutically acceptable salts of the compounds defined in the preceding claims.
- Claim 9: This claim covers pharmaceutical compositions comprising at least one compound of Claims 1-8 and a pharmaceutically acceptable carrier.
- Claim 10: Dependent on Claim 9, this claim specifies that the pharmaceutical composition is formulated for oral administration.
Key Method Claims (Claims 11-20):
- Claim 11: This independent claim describes a method of treating a retroviral infection in a subject. The method involves administering to the subject an effective amount of a compound of Claims 1-8 or a pharmaceutical composition of Claim 9. This is the primary therapeutic claim.
- Claim 12: Dependent on Claim 11, this claim specifies that the retroviral infection is an HIV infection.
- Claim 13: Dependent on Claim 11 or 12, this claim specifies that the method includes co-administering the claimed compound with at least one other antiretroviral agent. This highlights the potential for combination therapy.
- Claim 14: Dependent on Claim 13, this claim lists examples of other antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and integrase inhibitors.
- Claim 15: Dependent on Claim 11, this claim describes a method of inhibiting retrotransposon activity. This claim leverages the broader scope mentioned previously.
- Claim 16: Dependent on Claim 15, this claim specifies the inhibition of retrotransposons in eukaryotic cells.
- Claim 17: Dependent on Claim 11, this claim focuses on preventing or reducing the replication of a retrovirus in a subject.
- Claim 18: Dependent on Claim 17, this claim specifies that the retrovirus is HIV.
- Claim 19: Dependent on Claim 11, this claim describes a method of treating a viral infection by administering the claimed compound to a patient diagnosed with the infection.
- Claim 20: Dependent on Claim 19, this claim specifies that the viral infection is HIV.
The claims are structured to provide broad protection for the chemical class of compounds and their therapeutic applications, with specific examples and dependent claims providing fallback positions and detailing preferred embodiments.
What is the Patent Landscape for HIV Therapeutics and Related Nucleotide Analogs?
The patent landscape for HIV therapeutics, particularly nucleotide analogs, is highly competitive and mature. Major pharmaceutical companies have invested extensively in developing drugs that inhibit HIV replication, primarily targeting viral enzymes like reverse transcriptase, protease, and integrase.
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Nucleotide Reverse Transcriptase Inhibitors (NtRTIs): This class of drugs, which includes compounds similar in mechanism to those claimed in Patent 9,668,981, has been a cornerstone of HIV treatment for decades. Blockbuster drugs like Truvada (emtricitabine/tenofovir disoproxil fumarate), Descovy (emtricitabine/tenofovir alafenamide), and Epzicom (abacavir/lamivudine) are based on this mechanism. Patent 9,668,981 likely aims to protect novel NRTIs/NtRTIs with improved resistance profiles, reduced toxicity, or enhanced potency compared to existing therapies.
- Evergreening Strategies: Pharmaceutical companies often seek patent protection for new formulations, delivery methods, combination therapies, or improved analogs of existing drugs to extend market exclusivity. Patent 9,668,981 could represent such an effort by ViiV Healthcare, a company with a significant portfolio in HIV therapeutics (jointly owned by GSK, Pfizer, and Shionogi).
- Resistance Mutations: A significant challenge in HIV treatment is the development of drug resistance. The landscape is characterized by continuous research into compounds that are effective against resistant viral strains. Patent 9,668,981's claims likely address structural modifications that confer activity against common resistance mutations.
- Competition and Exclusivity: Many foundational patents for early NRTIs/NtRTIs have expired, leading to generic competition. However, newer generations of drugs and novel chemical entities continue to be patented. Companies like Gilead Sciences, Merck, and Bristol Myers Squibb are also active players in this space.
- Emerging Therapies: While NRTIs/NtRTIs remain critical, research is also advancing in other areas, including long-acting injectables, broadly neutralizing antibodies, and gene therapies. Patent 9,668,981 positions ViiV Healthcare within the established NRTI/NtRTI space, which continues to be a significant segment of the market.
The issuance of Patent 9,668,981 suggests ViiV Healthcare has identified specific chemical structures with potential therapeutic advantages, aiming to carve out a niche or improve upon existing treatments within the highly competitive HIV drug market.
How Does Patent 9,668,981 Potentially Affect the Market for Existing HIV Treatments?
The potential impact of Patent 9,668,981 on the existing HIV treatment market depends on several factors:
- Novelty and Efficacy: If the compounds claimed in Patent 9,668,981 demonstrate superior efficacy, reduced toxicity, or a better resistance profile compared to current NRTIs/NtRTIs, they could become preferred options for clinicians and patients, potentially displacing some existing treatments.
- Combination Therapies: The claims explicitly support use in combination therapy (Claim 13). If these novel analogs can effectively be combined with other drug classes, they could form the basis of new fixed-dose combinations, impacting the market share of existing combination therapies.
- Patent Expiry and Exclusivity: The patent's expiry date will determine the period of market exclusivity for ViiV Healthcare. Once the patent expires, generic versions could be introduced, increasing competition and potentially lowering prices for treatments based on these compounds.
- Market Segmentation: The patent could lead to market segmentation. For instance, if the compounds are particularly effective against specific resistant strains or have a favorable side-effect profile for certain patient populations, they might capture a specialized market segment.
- Licensing and Partnerships: ViiV Healthcare may choose to license the patent or its underlying compounds to other companies, leading to broader market penetration or the development of new therapeutic combinations by partners.
- Competition from Other Classes: The overall market is influenced by advancements in other HIV drug classes, such as integrase inhibitors and long-acting injectables. The success of treatments based on Patent 9,668,981 will be measured against these alternative therapeutic strategies.
Given that ViiV Healthcare is a major player in HIV, this patent likely represents an investment in their pipeline, aiming to maintain a competitive edge and extend their product lifecycle. The extent of its market impact will hinge on the clinical success and commercialization of the patented compounds.
What are the Key Dates and Status of Patent 9,668,981?
- Issue Date: June 6, 2017. This is the date the patent was granted and became legally enforceable in the United States.
- Filing Date: December 16, 2015 (as a continuation-in-part application). The initial filing date for the subject matter could be earlier, as is common with CIP applications, but this date signifies the filing of the specific application that led to Patent 9,668,981.
- Term Expiration: U.S. patents generally have a term of 20 years from the earliest effective filing date, subject to adjustments for patent term extensions (PTE). For a patent filed in December 2015, the standard expiration would be around December 2035. However, specific adjustments for regulatory review delays (PTE) could extend this term. The exact expiration date would require verification through the USPTO's Patent Term Calculator or official patent databases.
Status: As of its issue date in 2017, the patent is active and enforceable. The status of patents can change due to maintenance fees, litigation, or reexamination proceedings. Owners are required to pay maintenance fees at 3.5, 7.5, and 11.5 years after the grant date to keep the patent in force.
Who is ViiV Healthcare B.V. and What is Their Role in the HIV Market?
ViiV Healthcare B.V. is a global specialist HIV company established in 2009. It is dedicated solely to research, development, and commercialization of medicines for HIV. ViiV Healthcare is a joint venture formed by GlaxoSmithKline (GSK), Pfizer Inc., and Shionogi Limited.
- Ownership Structure: GSK holds a majority stake (around 77%), Pfizer holds a minority stake (around 13%), and Shionogi holds a minority stake (around 10%). This structure consolidates the HIV portfolios of these major pharmaceutical entities.
- Product Portfolio: ViiV Healthcare has developed and markets a broad portfolio of HIV medicines, including single-tablet regimens (STRs) and long-acting injectables. Notable products include:
- Triumeq: (dolutegravir, abacavir, lamivudine)
- Tivicay: (dolutegravir)
- Vemlidy: (tenofovir alafenamide)
- Jardiance (for HIV-negative individuals for PrEP): (cabotegravir/rilpivirine long-acting injectable)
- Cabenuva: (cabotegravir/rilpivirine long-acting injectable)
- Market Position: ViiV Healthcare is one of the leading companies in the global HIV market, with a strong focus on innovative treatments and addressing unmet medical needs in HIV prevention and treatment. Their investment in research and development, as evidenced by patents like 9,668,981, reflects their commitment to advancing HIV care.
- Strategic Focus: The company's strategy often involves developing drugs with improved dosing regimens (e.g., reducing pill burden, developing long-acting formulations), enhanced resistance profiles, and better tolerability.
The issuance of Patent 9,668,981 signifies ViiV Healthcare's continued efforts to expand its pipeline of novel HIV therapeutics, particularly within the well-established but still evolving class of reverse transcriptase inhibitors.
What is the Significance of "Selective Retro viral and Retrotransposon Polynucletide Analogs"?
The term "selective" is critical to understanding the therapeutic value of the compounds claimed in Patent 9,668,981.
- Selectivity for Viral vs. Host Enzymes: Retroviral replication relies on viral enzymes, primarily reverse transcriptase, to convert RNA into DNA. Human cells also utilize DNA polymerases for their own genetic processes. Nucleotide analogs that are not selective can be incorporated by host DNA polymerases, leading to cellular toxicity and adverse side effects. The "selectivity" of the analogs in this patent refers to their preferential inhibition of viral reverse transcriptase over human DNA polymerases. This enhanced selectivity is achieved through specific structural modifications to the nucleotide analog.
- Mechanism of Action: These analogs act as chain terminators. When a reverse transcriptase enzyme attempts to incorporate a nucleotide analog into a growing viral DNA chain, the unique structure of the analog (e.g., a modified 3' hydroxyl group on the sugar ring) prevents the addition of the next nucleotide. This effectively halts viral DNA synthesis and replication.
- Retrotransposon Inhibition: The inclusion of "retrotransposon" indicates that the analogs are designed to also inhibit the replication of these mobile genetic elements, which use a similar reverse transcriptase mechanism. While not directly pathogenic in the way HIV is, uncontrolled retrotransposon activity can contribute to genetic instability and certain diseases. The selective nature of the analogs suggests they could offer a therapeutic benefit without significantly impacting normal cellular DNA replication.
- Therapeutic Advantage: Selectivity translates to a better therapeutic index – the ratio between the toxic dose and the therapeutic dose. Highly selective agents can be administered at higher effective doses with a lower risk of significant toxicity, leading to better patient outcomes and adherence.
Therefore, the term highlights the core innovation: not just creating inhibitors of viral replication, but doing so in a way that minimizes harm to the host organism by targeting viral machinery specifically.
Key Takeaways
- Patent 9,668,981, issued to ViiV Healthcare B.V. in 2017, protects novel nucleotide analogs designed to inhibit retroviral and retrotransposon replication.
- The core innovation lies in the selective inhibition of viral reverse transcriptase over human DNA polymerases, achieved through specific chemical modifications to the nucleotide structure.
- The primary therapeutic target is HIV, with claims also extending to the inhibition of retrotransposons.
- Key claims cover the chemical compounds, pharmaceutical compositions, and methods for treating viral infections, specifically HIV, and for inhibiting retrotransposon activity.
- The patent operates within a highly competitive and mature HIV therapeutic landscape, particularly for nucleotide analog reverse transcriptase inhibitors (NRTIs/NtRTIs).
- Its market impact will depend on the demonstrated clinical efficacy, safety profile, and ability to overcome drug resistance compared to existing HIV treatments, as well as its patent term.
- ViiV Healthcare is a major specialist HIV company, and this patent represents its continued investment in expanding its innovative drug pipeline.
Frequently Asked Questions
-
What is the primary therapeutic application envisioned for the compounds protected by Patent 9,668,981?
The primary therapeutic application is the treatment of Human Immunodeficiency Virus (HIV) infection.
-
Besides HIV, what other biological entities are targeted by the claims in Patent 9,668,981?
The claims also encompass the inhibition of retrotransposon activity.
-
What is the principal mechanism by which the claimed nucleotide analogs inhibit viral replication?
The analogs function as chain terminators, preventing the elongation of viral DNA by irreversibly binding to and inhibiting the viral reverse transcriptase enzyme.
-
When was United States Patent 9,668,981 issued, and what is its general expiration timeline?
The patent was issued on June 6, 2017. Its standard term is 20 years from the earliest effective filing date, which was December 16, 2015, for the application leading to this patent, suggesting an approximate expiration around December 2035, subject to potential patent term adjustments.
-
What is the significance of the "selective" nature of the nucleotide analogs claimed in this patent?
The selectivity refers to their preferential inhibition of viral reverse transcriptase over human cellular DNA polymerases, which is intended to reduce host cell toxicity and improve the therapeutic index of potential treatments.
Citations
[1] ViiV Healthcare B.V. (2017). United States Patent 9,668,981: SELECTIVE RETROVIRAL AND RETROTRANSPOSON POLYNUCLETIDE ANALOGS AND METHODS FOR THEIR USE. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
